Median PFS per BICR in patients with tumor cell PD‐L1 expression ≥1% treated with nivolumab plus chemotherapy was 6.8 months (95% CI 5.7–8.3) versus 4.4 months (95% CI 2.9–5.8) with chemotherapy (HR 0.67 [95% CI 0.51–0.89]) (Figure 1C). This evidence concerns the gene CD274 and neoplasm.